drugset / Trial / NCT04692376

MSC for Treatment of cGVHD After Allo-HSCT

NCT04692376

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.

Timeline

Start
2021-01-10
Primary completion
2022-12-31
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous
Background Cyclosporine Peptide 2.5 mg/kg
Background Methylprednisolone Other / unclassified 1 mg/kg